. Plasminogen activated by human UK is possible (Table 1 ) and the situation is simplified by the fact that, in all mammals, plasminogen is activated by UK and SKHS, and in some by SK alone. The most variable factor is the level of circulating plasminogen activator. This cannot be correlated with plasminogen or fibrinogen levels or with observed stress or use of any anesthetic or tranquillizing drug but, broadly speaking, closely related mammals have similar activator levels. In some species, for example elephants and some bovine animals, the level of circulating plasminogen activator is immeasurably low in spite of the stress situation induced by taking blood samples. The highest levels have been found in new world monkeys (Cebida); these animals also show a rapid generation of intrinsic prothrombin activator and high concentrations of some clotting factors (Hawkey 1971 ) so, in this group, clotting and fibrinolytic activity are apparently increased in parallel. The average plasminogen level in monkeys and carnivores is higher than in man, implying greater potential fibrinolytic activity in these animals. As a general rule the plasminogen level in Artiodactyla is low. Free plasmin has not been detected in any mammal so far examined. Inhibitors of fibrinolysis are present in all mammals, and in monkeys and carnivores the average values of these do not differ significantly from those of man.
Considering these findings from an evolutionary point of view, a fibrinolytic enzyme has been identified in animals as far back as the cartilaginous fish, and at this stage it seems possible that inhibitors of the mechanism have not yet been developed. There is no evidence of an activator/ proenzyme stage in fish. Inhibitors are also apparently absent in some amphibians but in the clawed toad the full spectrum of fibrinolytic factors has been identified. Reptiles are odd in that they have no fibrinolytic mechanism but, in these animals, blood coagulation is held in check by the presence of a circulating anticoagulant. In birds the same fibrinolytic factors are present as in mammals although in some birds spontaneous fibrinolytic activity has not been found.
Methodological difficulties may account at least partially for our current inability to detect fibrinolysis in all animals capable of producing a fibrin clot (Hawkey 1970) . In mammals, where these are less evident, a parallel increase in both clotting and fibrinolysis has been demonstrated in new world monkeys, and many mammals which are 'hypercoagulable' compared with man also have higher plasminogen levels. At present the physiological pathways by which the fibrinolytic mechanism is activated in non-human species are not fully understood. Elucidation of these together with the collection of more comparative data is necessary before the physiological implications of the coagulation/fibrinolysis equilibrium can be fully assessed.
Dr J D Cash (Blood Transfusion Centre, Royal Infirmary, Edinburgh, EH3 9HB)
Fibrinolysis in Pregnancy
It is an interesting clinical fact that pregnant women may be especially prone to what can best be described as episodes of uncompensated disseminated intravascular coagulation, which lead to microcirculatory blockade. The clinical features of this phenomenon are variable but include acute renal cortical necrosis, acute renal tubular necrosis, Sheehan's syndrome and perhaps even eclampsia (McKay 1964) . The reasons for this heightened susceptibility are as yet not clear, but it is logical to consider a defective fibrinolytic enzyme system as one important factor.
Recent published studies in this area are in general agreement, that although there is a small but significant increase in the plasminogen concentration in pregnancy the most outstanding feature is a marked fall in the level of circulating plasminogen activator, beginning some time in the second trimester (Mitchell & Cope 1965 , Nilsson & Kullander 1967 , Bonnar et al. 1969 ). While there have been reports of an increase in anti-activator activity in the latter months of pregnancy (Brakman & Astrup 1963) this has not been confirmed by others (Nilsson & Kullander 1967 , Bonnar et al. 1969 .
The mechanisms responsible for the decreased plasminogen activator activity are unknown, but is interesting to note that after more than 3 months of depression it returns to non-pregnant values within an hour of placental separation , and that such changes in pregnancy and parturition closely parallel those observed in foetal-placental function derived from oestrogen studies (Roy & Mackay 1962 , Roy et al. 1963 ). However, although perhaps not strictly analogous, similar changes have not been observed during the administration of cestrogencontaining oral contraceptives (Brakman 1968) .
Whether depressed levels of plasminogen activator in late pregnancy represent diminished actual in vivo fibrinolysis has not yet been fully elucidated. The introduction of techniques to quantitate serum fibrin/fibrinogen degradation products (FDP) (Merskey et al. 1966 , Das 1970 has, however, provided the necessary stimulus to begin tentative studies in this area. Using the tained red cell hmmagglutination inhibition immunoassay, have shown that elevated serum FDP occurs in late pregnancy in the presence of depressed plasminogen activator. The cause of this elevation is unknown, but it has been suggested that it may represent minute episodes of occult disseminated intravascular coagulation in association with insignificant placental damage.
Other studies have shown that, in addition to a depressed resting level of plasminogen activator, a significant proportion of apparently healthy women in the third trimester of pregnancy develop a defect in the mechanisms leading to a release of circulating plasminogen activator following a physiological stimulus such as moderate exercise (Woodfield, Cole, Allan & Cash 1968) . Further evidence in support of this observation was obtained by the demonstration of an impaired response to surgery (elective Gesarean section) in pregnant women when compared to a non-pregnant group (hysterectomy) .
From these separate studies it is concluded that all normal pregnant women display a marked depression of circulating plasminogen activator in the later months of pregnancy. However, in perhaps as many as 25 % of these women, who appear to be entirely healthy, a further independent defect is acquired: an inability to mobilize plasminogen activator in response to physiological stimuli. It is postulated that, in the face of a major episode of disseminated intravascular coagulation, the primary clinical problem in those women with the single defect will be the control of bleeding. In the minority group, with a double plasminogen activator defect, microcirculatory blockade with associated tissue damage is likely to be a more sinister feature in terms of patient survival and clinical management. From the serum FDP studies it seems likely that, despite apparently lowered plasma plasminogen activator content in the second half of pregnancy, there is still more than sufficient residual local or systemic activity to cope with perhaps even a modest increase in demand in terms of normal daily wear and tear. However, the sudden release of large quantities of placental thromboplastic material may require a quite separate increment in excess of the 'nonspecific' response to surgery, in order to maintain homeostasis. The fact that all pregnant women do not develop a double defect in pregnancy is in line with clinical experience, which indicates that only a fraction of those with episodes of disseminated intravascular coagulation go on to develop such complications as renal cortical necrosis (Epstein et al. 1968 ).
